Tremor
TrialsCompanies

Not investment advice.

Tremor shows what changed in public records. It never tells anyone to buy or sell. Many trial edits are harmless paperwork. Data from ClinicalTrials.gov, the SEC, and the Federal Register.

PrivacyTerms

ARTVArtiva Biotherapeutics, Inc.Finished

AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Non Hodgkin Lymphoma

33Calmworry score, out of 100

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

  • Announced layoffs or restructuring

    Since Oct 27, 2026 · was worth 15, fading over time

    +13.4

  • Main results were due Oct 2025, none posted yet

    Counts until it's fixed

    +10

  • 4 insiders sold shares within a month

    Since Nov 2, 2026 · was worth 10, fading over time

    +9.5
Worry score33

Score over time

Stage
Phase 1/2
Patients
45 (final count)
Started
Mar 29, 2021
Main results expected
Oct 6, 2025
Fully finished
Oct 6, 2025
Results posted
not yet

What counts as success

The trial's main goal(s), called the “primary outcome.”

  • Phase 1: Safety and tolerability of AB-101 as monotherapy, and in combination with rituximab (including the DLBCL specific cohort) and in combination with bendamustine and rituximab.

    Measured over: From the ICF signature through 13 weeks after last study drug dose.

  • Phase 1, combination therapy: AB-101 clinical activity, determined by ORR

    Measured over: From baseline disease assessment through end of study participation.

  • Phase 1, combination therapy: Identify the recommended Phase 2 dose (R2PD) for AB-101.

    Measured over: From ICF signature through 13 weeks after last study drug dose.

  • Phase 2: Determine the efficacy profile of AB-101 in combination with rituximab or in combination with bendamustine and rituximab when administered to patients with R/R NHL of B-cell origin.

    Measured over: From baseline disease assessment through end of study participation.

Changes Tremor has spotted

No changes since Tremor started watching this trial.
Show details (technical version)

Score inputs

  • layoffs: base 15, now 13.4, since 2026-10-27, fades (half-life) · source filing
  • results_overdue: base 10, now 10, since 2025-10-06, no fading
  • insider_selling_cluster: base 10, now 9.5, since 2026-11-02, fades (half-life)

Raw record changes

  • none yet

Trial ID NCT04673617 · record last updated 2026-04-03 · checked 2026-11-09 06:30 UTC

See the official record on ClinicalTrials.gov (NCT04673617) ↗